Danish drugmaker Lundbeck A/S has filed for regulatory approval in Europe of its antidepressant vortioxetine, the first filing of a non-copy antidepressant in Europe in five years. Lundbeck said in a statement the European filing would be followed by filing for regulatory approval in Canada in the second half of this year, in the United States in the fourth quarter and in Japan next year. "I am very pleased that we now have filed vortioxetine in Europe as many people suffering from major depression still struggle to find an effective treatment," Head of Research and Development Anders Gersel Pedersen said in the statement on Thursday.
